(Q47733432)

5 February 2018

title

Vasohibin 2 is transcriptionally activated and promotes angiogenesis in hepatocellular carcinoma (English)

1 reference

5 February 2018

author name string

X Xue

1

1 reference

5 February 2018

W Gao

2

1 reference

5 February 2018

B Sun

3

1 reference

5 February 2018

Y Xu

4

1 reference

5 February 2018

B Han

5

1 reference

5 February 2018

F Wang

6

1 reference

5 February 2018

Y Zhang

7

1 reference

5 February 2018

J Sun

8

1 reference

5 February 2018

J Wei

9

1 reference

5 February 2018

Z Lu

10

1 reference

5 February 2018

Y Zhu

11

1 reference

5 February 2018

Y Sato

12

1 reference

5 February 2018

Y Sekido

13

1 reference

5 February 2018

Y Miao

14

1 reference

5 February 2018

Y Kondo

15

1 reference

5 February 2018

language of work or name

English

0 references

publication date

21 May 2012

1 reference

5 February 2018

published in

Oncogene

1 reference

5 February 2018

volume

32

1 reference

5 February 2018

issue

13

1 reference

5 February 2018

page(s)

1724-1734

1 reference

5 February 2018

https://scigraph.springernature.com/pub.10.1038/onc.2012.177

exact match

0 references

cites work

Angiogenesis and hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.177

Angiogenesis: an organizing principle for drug discovery?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.177

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.177

HCC and angiogenesis: possible targets and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.177

Vasohibin-1 in human breast carcinoma: a potential negative feedback regulator of angiogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.177

Isolation and characterization of vasohibin-2 as a homologue of VEGF-inducible endothelium-derived angiogenesis inhibitor vasohibin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.177

Distinctive localization and opposed roles of vasohibin-1 and vasohibin-2 in the regulation of angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.177

The language of covalent histone modifications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.177

Translating the Histone Code

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.177

Active genes are tri-methylated at K4 of histone H3

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.177

Role of histone H3 lysine 27 methylation in X inactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.177

Histone acetylation increases chromatin accessibility

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.177

Isolation of a small vasohibin-binding protein (SVBP) and its role in vasohibin secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.177

TNF/p38α/polycomb signaling to Pax7 locus in satellite cells links inflammation to the epigenetic control of muscle regeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.177

Inhibition of aldose reductase prevents angiogenesis in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.177

Vascular changes in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.177

Hypoxia and hepatocellular carcinoma: The therapeutic target for hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.177

Lessons from phase III clinical trials on anti-VEGF therapy for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.177

Tumor-surrogate blood vessel subtypes exhibit differential susceptibility to anti-VEGF therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.177

hsa-miR-520h downregulates ABCG2 in pancreatic cancer cells to inhibit migration, invasion, and side populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.177

Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.177

Does the EGFR and VEGF expression predict the prognosis in colon cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.177

May abnormal carotid intima-media thickness predict colorectal neoplasm?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.177

Roles of intrinsic angiogenesis inhibitor, vasohibin, in cervical carcinomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.177

NF-kappaB inhibition by an adenovirus expressed aptamer sensitizes TNFalpha-induced apoptosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.177

In vitro assays for endothelial cell functions related to angiogenesis: proliferation, motility, tubular differentiation, and proteolysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.177

Apigenin inhibits expression of vascular endothelial growth factor and angiogenesis in human lung cancer cells: implication of chemoprevention of lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.177

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/ONC.2012.177

1 reference

5 February 2018

1 reference

5 February 2018